TU Ilmenau Humbold Bau

Projektsuche


€

0 Projekte gefunden.


Nach den folgenden Parametern kann sortiert werden:

Titel
Hochschule
Fakultät/Einrichtung
Drittmittelgeber
Beginn Ende
Gesamtmittel
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
UKJ
Medizinische Fakultät
Cytokinetics, Inc.
2024 - 2025
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety ofLuspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to RevisedInternational Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-RiskMyelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participantswho are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial
UKJ
Medizinische Fakultät
Celgene Corporation
2024 - 2030
Kategorie 10.000,00 - 99.999,00 €
A Phase 3, Randomized, Active-Comparator-Controlled Clinical Study toEvaluate the Safety and Efficacy of Bomedemstat (MK-3543) versus Hydroxyurea inParticipants with Previously-Untreated Essential Thrombocythemia
UKJ
Medizinische Fakultät
MSD SHARP & DOHME GmbH
2024 - 2030
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
UKJ
Medizinische Fakultät
Chinook Therapeutics, Inc.
2024 - 2026
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)
UKJ
Medizinische Fakultät
Eli Lilly Cork Limited
2024 - 2026
Kategorie 10.000,00 - 99.999,00 €
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
UKJ
Medizinische Fakultät
MSD SHARP & DOHME GmbH
2024 - 2028
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
UKJ
Medizinische Fakultät
Celgene Corporation
2024 - 2030
Kategorie 10.000,00 - 99.999,00 €
Apricare – Bindung und Selbstmanagementfähigkeiten bei Patienten mit Multimorbidität
UKJ
Medizinische Fakultät
DFG
2015 - 2018
48.548,00 €
Apricare – Bindung und Selbstmanagementfähigkeiten bei Patienten mit Multimorbidität
UKJ
Medizinische Fakultät
DFG
2016 - 2017
13.160,00 €
A prospective, double-blind, randomized, parallel group,placebo-controlled, multicentre, Phase II study to investigate the efficacy,GPCR autoantibody-neutralizing effect, safety, and tolerability of BC 007in participants with long COVID
UKJ
Medizinische Fakultät
Berlin Cures GmbH
2024 - 2026
Kategorie 10.000,00 - 99.999,00 €
Projektsuche | Impressum | FAQ